Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters
Von Schwab N et al, erschienen in „Multiple Sclerosis“ (Vol. 24, Nr. 5, April 2018)